Kisunla

Active Ingredient(s): Donanemab-azbt
FDA Approved: * July 2, 2024
Pharm Company: * ELI LILLY CO
Category: Alzheimers / Dementia
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Kisunla 17.5 mg/ml Intravenous Injection, Solution
NDC: 0002-9401
Labeler:
Eli Lilly and Company